Riskpilot← Back to searchSign inGet full accessDYBWADSGYNEKOLOGENE DA
DAActiveOrg 918307613Dybwads gate 2, 0367 OsloMedical specialists activities · NACE 8622Est. 20173 employees
Revenue 2024
NOK 2,1M
-1% vs 2023
EBITDA margin
-5.1%
-493% vs 2023
Equity ratio
-53.3%
Financial strength
Net profit 2024
NOK -127K
-4011% vs 2023
| Revenue | NOK 2,1M | -1% |
| EBITDA | NOK -106K | -493% |
| Net profit | NOK -127K | -4011% |
| Total assets | NOK 167K | -36% |
| Equity | NOK -89K | -337% |
| Employees | 3 | — |
Legal name
DYBWADSGYNEKOLOGENE DA
Org number
918307613
Legal form
Ansvarlig Selskap Med Delt Ansvar
NACE code
8622 · Medical specialists activities
Founded
3. januar 2017
Share capital
—
Employees
3 (FTE)
VAT registered
No
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Company purpose
Drift av-, og kostnadsfordeling av fellesanskaffelser til-, legesenteret dybwadsgynekologene i dybwadsgate 2 i oslo og det som naturlig hører med til dette. Dybwadsgynekologene driver medisinsk virksomhet innen fødselshjelp og kvinnesykdommer.
Address
Dybwads gate 2, 0367 Oslo
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Revenue | 1 700 | 1 990 | 1 920 | 2 100 | 2 070 |
| Staff expenses | −954 | −1 112 | −1 085 | −1 201 | −1 217 |
| EBITDA | 13 | 57 | 12 | 27 | −106 |
| Depreciation & amort. | −10 | −15 | −15 | −21 | −21 |
| EBIT | 3 | 42 | −3 | 6 | −127 |
| Net financials | −3 | −10 | 1 | −3 | 0 |
| Profit before tax | 0 | 32 | −2 | 3 | −127 |
| Tax | −0 | −0 | −0 | −0 | −0 |
| Net profit | 0 | 32 | −2 | 3 | −127 |
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Total assets | 169 | 279 | 241 | 262 | 167 |
| Equity | 0 | 32 | 29 | 38 | −89 |
| Long-term debt | 0 | 0 | 0 | 0 | 0 |
| Short-term debt | 169 | 248 | 212 | 224 | 257 |
| Total debt | 169 | 248 | 212 | 224 | 257 |
EBITDA margin
-5.1%
This company
15.8%
Market median
-132% vs market
20202024
Equity ratio
-53.3%
This company
38.2%
Market median
-240% vs market
20202024
Return on equity
-12694500.0%
This company
18.4%
Market median
-68991948% vs market
20202024
Net profit margin
-6.1%
This company
8.1%
Market median
-175% vs market
20202024
Asset turnover
12.37×
This company
1.12×
Market median
+1004% vs market
20202024
Debt / equity
2.87×
This company
0.62×
Market median
-363% vs market
20202024
- Annual report 2024Filed via Brønnøysundsregistrene · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Brønnøysundsregistrene · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Brønnøysundsregistrene · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Brønnøysundsregistrene · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via Brønnøysundsregistrene · Period 2020-01-01 – 2020-12-31
| Name | Role | Member since |
|---|---|---|
| Current (1) | ||
CF Chief Executive Officer | Chief Executive Officer | 2020 |
No data on file.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of DYBWADSGYNEKOLOGENE DA also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Catarina Falck | Chief Executive Officer | 0 companies |